Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition containing inorganic arsenic compounds and application thereof

A composition and inorganic arsenic technology, which can be used in pharmaceutical combinations, medical preparations containing active ingredients, inorganic active ingredients, etc., can solve the problem of insufficient activity, and achieve the advantages of reducing systemic toxicity, reducing therapeutic dose and application safety. Effect

Active Publication Date: 2016-12-14
NANTONG YUFUYUAN PHARMA CO LTD
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

More and more studies have found that scutellarin and its derivatives show good application prospects in the field of anti-tumor, but the activity is not strong enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing inorganic arsenic compounds and application thereof
  • Medicine composition containing inorganic arsenic compounds and application thereof
  • Medicine composition containing inorganic arsenic compounds and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0015] Breast cancer MDA-MB-231 cells in the logarithmic growth phase were seeded in 96-well plates, 3×10 per well 3 cells. Set CO 2 Samples were added after 24 hours of incubation at 37°C in an incubator. 10 μL of PBS solution was added to the control group; 5 μL of PBS solution and 5 μL of arsenic trioxide solution were added to the arsenic trioxide group; Wherein the final concentrations of scutellarin and scutellarin aglycone are respectively μmol L -1 , each group was set up with 6 multiple wells, and each experiment was repeated 3 times. Put in 37°C CO 2 in the incubator. After 48 hours, add 20 μL MTS solution, 37°C CO 2 Continue to incubate in the incubator for 2 hours, and measure the absorbance (A) at 490 nm with an automatic microplate reader. All of the above were completed under the funding of Yunnan Collaborative Innovation Center for Public Health and Disease Prevention and Control (2016YNPHXT15).

[0016] The specific result is

[0017] Table 1 Inhibito...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition containing inorganic arsenic compounds and application thereof. The medicine composition comprises inorganic arsenic compounds, scutellarin or scutellarein, is used for preparing medicines for treating cancers, and has a better effect on cancer cell inhibition than that by singly using inorganic arsenic compounds and that by singly using scutellarin or scutellarein. According to the medicine composition, the treatment dosage of inorganic arsenic compounds can be reduced, the cancer inhibition effect can be enhanced, and the systematic toxin of inorganic arsenic compounds can be effectively reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing an inorganic arsenic compound and its application, in particular to a pharmaceutical composition containing an inorganic arsenic compound and scutellarin or scutellarin aglycon, and its preparation for treating cancer drug application. Background technique [0002] In 1971, Han Taiyun of the First Affiliated Hospital of Harbin Medical College transformed a Chinese medicine containing arsenic into a medicine for treating leukemia. In 1973, Zhang Tingdong, Zhang Peng, etc. applied "Ailing No. 1" to treat chronic myeloid leukemia, which improved the hematological indicators and clinical symptoms of patients. It has been proved that the inorganic compound arsenic trioxide can treat relapsed or refractory acute promyelocytic leukemia (APL), and recent preliminary data show that arsenic trioxide also has an effect on other cancers, so the study of arsenic trioxide as an anticancer drug is one ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/36A61P35/00A61K31/7048A61K31/352
CPCA61K31/352A61K31/7048A61K33/36A61K2300/00
Inventor 何越峰尚莉平妮娜王立萍姚树祥张若冰
Owner NANTONG YUFUYUAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com